OClawVPS.com
Lundbeck
Edit

Lundbeck

http://www.lundbeck.com/
Last activity: 18.03.2026
Active
Categories: BiotechHealthcareNeurologyPharmaceuticalPsychiatry
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Despite the challenges, Lundbeck remains steadfast in our commitment to deliver innovation that patients need. We work tirelessly to advance neuroscience, develop new and innovative treatments, and support patient communities – all with the aim of restoring brain health and transforming the lives of the millions of people living with a brain disease. Not only does the burden of brain diseases demand action now, it also demands expertise and courage. We know that to get radically different results, we need to pursue radically different approaches.

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing, and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and California and our production facilities are located in Denmark, France, and Italy.

For additional information, we encourage you to visit our corporate site www.lundbeck.com.

The privacy statement and applicable disclaimer for this company page can be found here: https://www.lundbeck.com/global/linkedin-privacy-notification-and-disclaimer
Likes
587
Website visits
113.1K /mo.
Mentions
181
Location: Denmark
Employees: 5001-10000
Phone: +48 12 348 68 88
Founded date: 1915

Investors 2

Mentions in press and media 181

DateTitleDescription
22.03.2026Europe's Corporate Evolution: AGM Insights and Sustainability ImperativesEuropean firms Lundbeck and Posti Group recently unveiled key corporate updates. Lundbeck's AGM approved dividends, new board members, and a share repurchase. Posti released its 2025 Annual Report, highlighting financial results and robust ...
18.03.2026Lundbeck held its Annual General Meeting on 18 March 2026 at the company’s registered officeLundbeck held its Annual General Meeting on 18 March 2026 at the company’s registered office Wed, Mar 18, 2026 13:00 CET Report this content H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted an...
16.03.2026Lundbeck advances Parkinson’s research with new Phase 1b data at AD/PD™ 2026Lundbeck advances Parkinson’s research with new Phase 1b data at AD/PD™ 2026 Mon, Mar 16, 2026 09:00 CET Report this content Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease, to be prese...
10.03.2026Lundbeck appoints Chief AI OfficerLundbeck appoints Chief AI Officer Tue, Mar 10, 2026 09:00 CET Report this content Valby, Denmark, 10 March 2026 – H. Lundbeck A/S (Lundbeck) today announced the appointment of Markus Kede as Senior Vice President, Chief AI Officer. He will...
09.03.2026Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trialLundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial Mon, Mar 09, 2026 10:33 CET Report this content MASCOT is a first-of-its-kind, Phase 3 trial supporting the development of amlenetug, an investigational th...
03.03.2026BioInnovation Institute backs five startups with €1.3M in follow-on fundingBioInnovation Institute (BII), an initiative of the Novo Nordisk Foundation, has awarded an additional €1.3 million in follow-on funding to five portfolio startups, bringing total support per company to up to €1.8 million. The funding is in...
26.02.2026Slate Medicines Secures $130M to Advance Migraine PreventionSlate Medicines secures $130 million in Series A funding. The Raleigh, NC-based biotech company launched to transform migraine prevention. Its core focus is SLTE-1009, an anti-PACAP monoclonal antibody. This therapy addresses severe headach...
24.02.2026Slate Medicines: $130 Million Series A Raised To Advance Anti-PACAP Migraine TherapiesSlate Medicines, a privately held biotech company developing next-generation therapeutics for headache disorders, has launched with the close of a $130 million Series A financing and the in-licensing of SLTE-1009, an anti-PACAP monoclonal a...
18.02.2026Transactions with shares and linked securities in Lundbeck made by executives and their closely associated partiesTransactions with shares and linked securities in Lundbeck made by executives and their closely associated parties Wed, Feb 18, 2026 09:32 CET Report this content 1. Details of the person discharging managerial responsibilities / person clo...
17.02.2026To the shareholders of H. Lundbeck A/STo the shareholders of H. Lundbeck A/S Tue, Feb 17, 2026 10:00 CET Report this content NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: WEDNESDAY, 18 MARCH 2026 AT 10:00...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In